Spravato, a ketamine nasal spray, is being subsidized for treatment-resistant depression. Learn about its benefits, usage, and eligibility criteria.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making it much cheaper for the e. Tuesday, 02 January 2024 12:17 GMT.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

A nasal spray that uses a form of ketamine to treat stubborn depression will be added to the PBS, making treatment cheaper for thousands of Australians. It is the first new depression medication ...

After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual ...

Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019 , but could only be prescribed ...

A nasal spray derived from ketamine is being used to address treatment-resistant depression. The treatment will be more accessible for up to 30,000 Australians ...

Esketamine, a form of ketamine taken as a nasal spray, has been approved for the treatment for moderate to severe ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...